Healthcare entity
Weiss Ratings is most often covered alongside Wall Street Zen, which appears in 5 of these 7 stories. Against the same-window beat baseline of 26% negative, this entity's 0% share is less negative. Source depth averages 2.3 original sources per story, versus 3.6 across the same-window beat baseline.
Last mentioned: 1d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Weiss Ratings is most often covered alongside Wall Street Zen, which appears in 5 of these 7 stories. Against the same-window beat baseline of 26% negative, this entity's 0% share is less negative. Source depth averages 2.3 original sources per story, versus 3.6 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6 for that window. Across a 40-day span, the pace is roughly 1.2 stories per week. The busiest single day carried 2. Coverage clusters in market-trends, which accounts for 4 of those 7, with the remainder spread across 2 other categories. We currently track 7 Healthcare stories that mention Weiss Ratings, published between July 5, 2026 and August 13, 2026.
Computed from the 7 stories linked to this entity, with beat comparisons drawn from all 372 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Weiss Ratings. Shared-story counts are live from our verified record — not editorial picks.
Q2 2026 Earnings Release
Company reported EPS of ($0.19), missing consensus by $0.03.
Ladenburg Thalmann Upgrade
Ladenburg Thalmann upgraded CRVS to ‘strong-buy’.
Weiss Ratings Upgrade
Weiss Ratings upgraded Corvus from ‘sell (e+)’ to ‘sell (d-)’.
Director Insider Purchase
Director David Scott Moore acquired 21,700 shares at $11.53 per share, totaling $250,201.
Wall Street Zen Downgrade
Wall Street Zen downgraded CRVS from ‘hold’ to ‘sell’.
Goldman Sachs Initiates Coverage
Goldman Sachs issued a ‘buy’ rating and a $40.00 target price for Corvus Pharmaceuticals.
For healthcare and medical device stakeholders, Apyx Medical's Q1 revenue of $12.49 million beat consensus by $1.96 million, yet the stock fell 1.8% to $4.38. The decline on 60% below-average volume suggests limited conviction, while analysts maintain a moderate buy rating and $6.50 target. The company's strong liquidity ratios contrast with its negative net margin and return on equity.
Ensysce Biosciences short interest soared 619.9% to 364,278 shares as its stock trades at $0.30, while Focus Universal posted just $0.05M in quarterly revenue. The data highlights severe financial fragility across two small healthcare and device innovators.
Corvus Pharmaceuticals missed Q2 EPS by $0.03, highlighting the financial fragility of early-stage oncology R&D. With no near-term data readouts, the miss draws attention to cash burn and the critical need for clinical progress to justify its $1.17B valuation.
Source: dailypolitical.com · tickerreport.com
Teva Pharmaceutical's FY2026 EPS guidance fell short of the $2.17 consensus, while revenue projections of $16.5-$16.9B matched expectations. For healthcare leaders, the miss underscores ongoing generic drug pricing pressures and the importance of a diversified pipeline.
Wall Street Zen downgraded vaccine maker Novavax to sell, raising alarms in the healthcare sector. The stock traded at $7.41, far below its $13 consensus target, with a negative P/E of -12.78.
Analyst downgrades reflect growing fears that GLP-1 weight loss drugs could erode the sleep apnea device market, even as ResMed’s financials stay solid. The contrast between a $225 low target and $321 high target underscores sector uncertainty.
A major Shuttle Pharmaceuticals shareholder just poured $110,694 into the beaten-down stock, buying 32,591 shares at near all-time lows. For healthcare investors, this insider vote of confidence in a radiation oncology developer could signal upcoming clinical catalysts or a potential turnaround.
Weiss Ratings is linked from 7 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
